Check the time stamp on this data. Updated AI-Generated Signals for Sarepta Therapeutics Inc. (SRPT) available here: SRPT.

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Piper Sandler analyst Biren Amin maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target of ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price ...

Quantbot Technologies LP bought a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) during the 3rd quarter, according to its most recent filing with the Securities and ...

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price objective cut by HC Wainwright from $80.00 to $75.00 in a research report released on Tuesday morning,Benzinga reports.They ...

The share price in Arrowhead Pharmaceuticals Inc. jumped by more than 48% in the two months since it hit its lowest value of the past year. On Oct. 10, ...

European regulators are to review Sarepta Therapeutics’ Duchenne muscular dystrophy drug, eteplirsen – a drug that has sparked controversy in the US, where it was approved by the FDA against ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sarepta is currently testing SRP-9001 in the placebo-controlled EMBARK study, which aims to enrol 120 boys with DMD aged four to seven and is due to read out in the latter half of 2023.

I saw the “Wicked” movie last week and haven’t been able to stop thinking about it. Just know that every word I’ve written ...